Abbott Laboratories Inc
The suburban Chicago drugmaker said on Wednesday that it had earned $1.44 billion, or 92 cents per share, compared with $938 million, or 60 cents per share, a year earlier.
It had a gain of $797 million related to derecognition of a contingent liability, and the company also received contractual payments from longtime partner Takeda Pharmaceutical Co Ltd <4502.T>.
Excluding special items, the company earned 73 cents per shares. Analysts on average expected 70 cents, according to Reuters Estimates.
Global sales fell slightly to $6.72 billion in the quarter, below the Reuters Estimates forecast of $7.07 billion. Abbott said sales were badly hurt by the stronger dollar, which reduces the value of overseas sales.
The company said it still expected full-year 2009 earnings of $3.65 to $3.70 per share, excluding special items. It forecast a profit of 87 cents to 89 cents per share for the second quarter.
(Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)